0.264
-0.02 (-7.38%)
| Previous Close | 0.285 |
| Open | 0.280 |
| Volume | 254,693 |
| Avg. Volume (3M) | 1,384,059 |
| Market Cap | 48,303,116 |
| Price / Sales | 0.670 |
| Price / Book | 28.85 |
| 52 Weeks Range |
| Profit Margin | -159.10% |
| Operating Margin (TTM) | -155.29% |
| Diluted EPS (TTM) | -0.610 |
| Quarterly Revenue Growth (YOY) | 42.70% |
| Current Ratio (MRQ) | 0.140 |
| Operating Cash Flow (TTM) | 11.43 M |
| Levered Free Cash Flow (TTM) | 32.73 M |
| Return on Assets (TTM) | -57.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Bullish | Bullish |
| Drug Manufacturers - General (Global) | Bullish | Bullish | |
| Stock | Scilex Holding Company | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Small Core |
| % Held by Insiders | 25.93% |
| % Held by Institutions | 20.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Murchinson Ltd. | 31 Dec 2024 | 663,705 |
| Rafferty Asset Management, Llc | 31 Dec 2024 | 620,131 |
| 52 Weeks Range | ||
| Median | 18.00 (6,728.53%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 02 Apr 2025 | 18.00 (6,728.53%) | Buy | 0.298 |
| 28 Feb 2025 | 22.00 (8,245.98%) | Buy | 0.236 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |